Chronic wounds create large healthcare costs and complicate patient healing. Biofilms are a recurring cause of such wounds due to their resilience to antibiotics. Currently, there are no outstanding treatments. The standard of care is debridement followed by antibiotics, however these infections can be hard to treat because of the biofilms. This is in part because the extra polymeric substance (EPS), which is the backbone of biofilms, creates physical and chemical barriers to antibiotics.
This technology is a specific combination of enzymes that have the ability to dismantle and degrade the biofilm EPS infrastructure done in combination with an antibiotic. This can facilitate the healing process without the downside of debridement.
-Permits the treatment of resistant bacterial infections
-Confers renewed usability to antibiotics that traditionally lacked the efficacy in biofilm environments
-Chronic wound healing
A U.S. Provisional Patent application, Serial 62/698346 was filed on 7/16/2018
Strong animal efficacy data has been obtained.
Kendra Rumbaugh, Professor, Department of Surgery, Texas Tech University Health Science Center, Lubbock, Texas.
Derek Fleming, Graduate Student, Department of Surgery, Texas Tech University Health Science Center, Lubbock, Texas.
Biofilm infection, biofilm treatment, chronic would treatment, oral wound treatment, ocular infection treatment and sinus infection treatment.